Page last updated: 2024-10-28

hydroxychloroquine and Granulocytic Leukemia, Chronic, Stable Phase

hydroxychloroquine has been researched along with Granulocytic Leukemia, Chronic, Stable Phase in 1 studies

Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Eşkazan, AE1

Other Studies

1 other study available for hydroxychloroquine and Granulocytic Leukemia, Chronic, Stable Phase

ArticleYear
Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?
    Leukemia, 2020, Volume: 34, Issue:12

    Topics: Cytogenetic Analysis; Humans; Hydroxychloroquine; Imatinib Mesylate; Leukemia, Myelogenous, Chronic,

2020